clinical trial · NCT04567303
Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration
Macular DegenerationZifibancimigRanibizumabPort Delivery Platform
brief summary
This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the port delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD).
started
Oct 28, 2020
primary completion
Aug 1, 2026
completion
Aug 1, 2026
last updated
May 6, 2026
official title
A Three-part, Phase I/II Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Zifibancimig Following Intravitreal Administration of Multiple Ascending Doses and Continuous Delivery From the Port Delivery in Patients With Neovascular Age-related Macular Degeneration
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol